Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00117689 | Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection | PHASE2 | COMPLETED | 75 | — | — | Apr 1, 2005 | Dec 1, 2007 | Mar 18, 2015 | 16 | United States, Canada |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Standard (tacrolimus based standard therapy without induction) |
| 2 Standard of Care | ACTIVE_COMPARATOR | Thymoglobulin with tacrolimus and corticosteroid sparing maintenance therapy |
| Name | Type | Description |
|---|---|---|
| Thymoglobulin | BIOLOGICAL | Antibody inductions with tacrolimus and corticosteroid sparing maintenance therapy |
| Corticosteroid | DRUG | For a minimum of 3 months |
| Tacrolimus | DRUG | Between Day 3 the last dose of Thymoglobulin |
| Mycophenolate Mofetil | DRUG | for at least 1 month posttransplant |
Inclusion Criteria: * Primary liver transplant recipient with Model for End-Stage Liver Disease (MELD) criteria documentation * Serum creatinine \> 1.5mg/dL at the time of transplant, or based on the value used to calculate the most recent pre-operative MELD Score for liver allocation * Ages greate...